Search - tctmd.com

Displaying 1 - 20 of 102

Sort: Relevancy | Date

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

Todd Neale

November 08, 2025

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Todd Neale

September 03, 2025

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News TCT 2024

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

Yael L. Maxwell

October 29, 2024

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News EACTS 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

Michael O'Riordan

October 13, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Advertisement

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Surgeons Support Proposed Changes to Left Main CAD Guidelines

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content